Fierce Pharma
MAY 1, 2024
Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. | Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. And it involves a major organizational restructuring.
MedCity News
MAY 1, 2024
Walmart’s decision to shutter its healthcare division reflects just how difficult it is to achieve profitability in the primary care and telehealth markets. Experts think retailers simply aren’t prepared to handle the bevy of challenges that come along with delivering healthcare — but could this news also be a sign of the system being broken? The post Healthcare Is a Frontier Not Even Walmart Could Conquer — And It’s Not Looking Great For Others Either appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 1, 2024
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. | Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.
Pharmaceutical Technology
MAY 1, 2024
AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.
Fierce Pharma
MAY 1, 2024
It’s no secret that U.S. biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing services. | Facing a push for China-U.S. decoupling from Washington, the industry trade group BIO now wants to quantify the U.S.’s dependence on Chinese CDMOs through a survey.
Clarivate
MAY 1, 2024
Learn about our generative AI-powered Web of Science Research Assistant, which will be available from September 2024. Last year, we announced our collaboration with the research community to bring a new generative-AI-powered capability to the Web of Science — the Web of Science Research Assistant. Since we released the beta to our development partners around the world, we have identified innovative ways to ensure the quality, strength and suitability of generative AI for academic researchers.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaVoice
MAY 1, 2024
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.
Fierce Pharma
MAY 1, 2024
J&J subsidiary floats $6.
MedCity News
MAY 1, 2024
In a discussion led by Aneesh Chopra, president of CareJourney, health tech organizations and providers discussed the protected health information (PHI) consent gaps and complex workflows impeding interoperability, and how companies such as Docusign are addressing them. The post The Evolution of eConsent Management for Mental Health, Substance Use Disorders Data appeared first on MedCity News.
pharmaphorum
MAY 1, 2024
FTC sends more warnings to pharma companies over 'junk' patents to protect drugs from generic competition, including Novo Nordisk's Ozempic.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
MAY 1, 2024
Communication with patients should be a top area of focus as urgent cares look to develop their marketing strategies, tailored to each generation they are trying to reach, with an eye toward relieving unnecessary demand on emergency departments. The post Generational Intel: Helping Patients Identify Where to Seek Care appeared first on MedCity News.
pharmaphorum
MAY 1, 2024
The MHRA's regulatory sandbox for artificial intelligence as medical device technologies, AI-Airlock, will go live this spring, according to a new strategy document
MedCity News
MAY 1, 2024
The MedTech industry is poised for breakthroughs, owing to the rapid integration of digital ecosystems and technologies like AI and cloud. The post Prioritizing Patient Care: Medical Technology Innovations on the Horizon appeared first on MedCity News.
pharmaphorum
MAY 1, 2024
Polish drug delivery company Biotts says it has demonstrated delivery of insulin across the skin for the first time without the use of an injection system.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
MAY 1, 2024
A new state-of-the-art research and laboratory building is being built on AbbVie’s main campus at its Rhineland-Palatinate site, the company ’s second largest research and development ( R&D ) location globally. The central research building LUdwighafens neue Arbeitswelt (LUnA) will benefit from an investment of approximately €150 million. Currently, the Rhineland-Palatinate site has over 2,000 employees, and LUnA will house over 300 researchers and scientists, according to AbbVie.
pharmaphorum
MAY 1, 2024
China's Jacobio Pharma is preparing to file its KRAS inhibitor glecirasib for approval, saying it could offer a safety advantage over current drugs in the class
European Pharmaceutical Review
MAY 1, 2024
By providing pharma companies with a real-life replicable model of a cloud-first manufacturing facility, we will drive forward the digital capability of pharma manufacturers” A new digital collaboration is set to take advantage of a manufacturing facility model featuring innovative technologies, accelerating how fast new medicines are made. The Centre for Process Innovation (CPI), academia, and the pharma industry will work together to develop the model which will harness artificial intell
Pharmaceutical Technology
MAY 1, 2024
Eli Lilly has announced that its net income rose to $2.24bn in Q1 2024, a 67% increase from $1.34bn in the same period of 2023.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
MAY 1, 2024
GSK's recovery gathers pace, with a strong Q1 prompting a rise in sales and earnings forecasts for the full-year.
PharmaTech
MAY 1, 2024
At INTERPHEX 2024, Pharmaceutical Technology® chatted with Dennis Powers from G-CON Manufacturing about podular cleanroom options and the benefits they offer for manufacturers.
PharmaTimes
MAY 1, 2024
Bladder cancer, including papillary tumours, is the ninth most common cancer type worldwide
MedCity News
MAY 1, 2024
Pepper Bio has licensed rights to lerociclib, a molecule that G1 Therapeutics designed to offer dosing and safety advantages over approved therapies in the same drug class. EQRx previously held rights to the drug, but returned them after the company was acquired last year. The post Pepper Bio’s ‘Google Maps for Drug Discovery’ Finds Way to Potential New Liver Cancer Drug appeared first on MedCity News.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTimes
MAY 1, 2024
The progressive neurological condition affects more than six million people worldwide
PharmaTech
MAY 1, 2024
The CDMO plans to expand and upgrade its Philadelphia, Ohio, and Milan facilities to meet the continued growth in demand for high potency handling capabilities.
Pharmaceutical Technology
MAY 1, 2024
Novartis and Japanese biopharmaceutical company PeptiDream have expanded their partnership for the discovery of peptides.
Clarivate
MAY 1, 2024
Are the powerful weight loss and diabetes treatments a lose-lose for medical technology companies? Not necessarily. The meteoric rise in popularity of a class of drugs for diabetes and weight loss has been weighing on medtech stocks. GLP-1 drugs like semaglutide (Ozempic®/Wegovy®) and tirzepatide (Mounjaro®/Zepbound®) spooked investors who feared that these treatments could disrupt a number of medical technologies, including surgical obesity interventions and orthopedics.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
MedCity News
MAY 1, 2024
A new eBook from HLTH and MedCity News captures how health insurers and their partners are using health tech to improve the patient experience, hea The post Shifting the Payer Landscape with Health Tech appeared first on MedCity News.
PharmaTech
MAY 1, 2024
Deitz’s Pharmafill TC4 tabletop tablet counter is suitable for counting and filling capsules, gelcaps, pills, softgels, and other opaque, translucent, and transparent oral solid dosage forms.
Evolve Your Success
MAY 1, 2024
Unlock the secrets of thriving in the cutthroat realm of vaccine sales with Jerome Pinson from CSL Seqirus as he shares potent strategies for standing out among industry behemoths. With his seasoned expertise, he paints a vivid picture of a day in the life of a medical sales pro, from the meticulous crafting of pre-call plans to the artful communication required to resonate with diverse healthcare audiences.
PharmExec
MAY 1, 2024
In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses the changing dynamics today for companies in revenue management and planning—and the increasing importance of a well-tooled and well-trusted analytics component in fueling product launch, M&A, and other data-centered pursuits.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
301 
Let's personalize your content